Therapeutic options to decrease actinic keratosis and squamous cell carcinoma incidence and progression in solid...

Area of Science:

• Dermatology
• Transplant Medicine
• Oncology

Background:

• Solid organ transplant recipients (SOTRs) exhibit a 50-250x increased risk of squamous cell carcinoma (SCC) compared to the general population.
• Immunosuppressive medications used in SOTRs contribute to higher rates of invasive and metastatic SCC.
• Increasing transplant numbers and recipient longevity elevate SCC as a significant cause of morbidity and mortality in SOTRs.

Purpose of the Study:

• To provide a practical clinical guide for managing SCC in SOTRs.
• To outline assessment, treatment, and management strategies for SCC in transplant recipients.
• To address the role of dermatologists within transplant teams and guide therapeutic choices.

Main Methods:

• Comprehensive literature review on SCC pathophysiology and treatment in SOTRs.
• Synthesis of current understanding to create a clinical approach.
• Focus on practical application for clinicians.

Main Results:

• A concise guide for managing actinic keratoses and SCC in SOTRs is presented.
• The guide offers a logical framework for clinical decision-making.
• Highlights practical considerations for topical, systemic, and immunosuppressive therapy adjustments.

Conclusions:

• Effective management of SCC in SOTRs requires thorough patient assessment.
• Understanding and applying diverse therapeutic alternatives is key.
• Early implementation of preventative and adjuvant therapies can reduce SCC-related mortality and morbidity in SOTRs.